Catumaxomab (Removab) and MT110, both targeting epithelial cell adhesion molecule (EpCAM) and CD3, were investigated in various cancers such as ovarian and gastric cancer in phase II or III clinical trials [75]. Here, EPCAM is linked to cancer.